Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Dickinson

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice dailyMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
AIDS Research and Human Retroviruses|August 17, 2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir dosesMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Antiviral Therapy|January 24, 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjectsAkil Jackson, Graeme Moyle, Laura Dickinson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
HIV Clinical Trials|March 18, 2015
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of ageJaime H Vera, Akil Jackson, Laura Dickinson, et al.
Antiviral Therapy|April 6, 2012
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adultsAlessandro Schipani, Deirdre Egan, Laura Dickinson, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
AIDS (London, England)|March 4, 2011
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancyLaura J Else, Fiona Lyons, Siobhan O'shea, et al.
Antiviral Therapy|April 14, 2010
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patientsLucy Garvey, Ngaire Latch, Otto W Erlwein, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice dailyMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
AIDS Research and Human Retroviruses|August 17, 2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir dosesMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Antiviral Therapy|January 24, 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjectsAkil Jackson, Graeme Moyle, Laura Dickinson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
HIV Clinical Trials|March 18, 2015
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of ageJaime H Vera, Akil Jackson, Laura Dickinson, et al.
Antiviral Therapy|April 6, 2012
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adultsAlessandro Schipani, Deirdre Egan, Laura Dickinson, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
AIDS (London, England)|March 4, 2011
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancyLaura J Else, Fiona Lyons, Siobhan O'shea, et al.
Antiviral Therapy|April 14, 2010
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patientsLucy Garvey, Ngaire Latch, Otto W Erlwein, et al.
Pageof 6